Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Intentional and Unintentional Nonadherence to Hydroxyurea Among People With Sickle Cell Disease: A Qualitative Study
source: Blood Advances
year: 2020
authors: Jason R. Hodges, Shannon M. Phillips, Sarah Norell, Chinonyelum Nwosu, Hamda Khan, Lingzi Luo, Sherif M. Badawy, Allison King, Paula Tanabe, Marsha Treadwell, Lucia Rojas Smith, Cecelia Calhoun, Jane S. Hankins, Jerlym Porter
summary/abstract:Hydroxyurea is an efficacious treatment for sickle cell disease (SCD), but adoption is low among individuals with SCD. The objective of this study was to examine barriers to patients’ adherence to hydroxyurea use regimens by using the intentional and unintentional medication nonadherence framework. We interviewed individuals with SCD age 15 to 49.9 years who were participants in the Sickle Cell Disease Implementation Consortium (SCDIC) Needs Assessment. The intentional and unintentional medication nonadherence framework explains barriers to using hydroxyurea and adds granularity to the understanding of medication adherence barriers unique to the SCD population. In total, 90 semi-structured interviews were completed across 5 of the 8 SCDIC sites. Among interviewed participants, 57.8% (n = 52) were currently taking hydroxyurea, 28.9% (n = 26) were former hydroxyurea users at the time of the interview, and 13.3% (n = 12) had never used hydroxyurea but were familiar with the medication.
Using a constructivist grounded theory approach, we discovered important themes that contributed to nonadherence to hydroxyurea, which were categorized under unintentional (eg, Forgetfulness, External Influencers) and intentional (Negative Perceptions of Hydroxyurea, Aversion to Taking Any Medications) nonadherence types. Participants more frequently endorsed adherence barriers that fell into the unintentional nonadherence type (70%) vs intentional nonadherence type (30%). Results from this study will help SCD health care providers understand patient choices and decisions as being either unintentional or intentional, guide tailored clinical discussions regarding hydroxyurea therapy, and develop specific, more nuanced interventions to address nonadherence factors.
organization: St. Jude Children’s Research Hospital, USA; Medical University of South Carolina, USA; University of Illinois, USA; Washington University in St. Louis, USA; Ann & Robert H. Lurie Children’s Hospital of Chicago, USA; Duke University, USA; University of California San Francisco Benioff Children’s Hospital Oakland, USA; RTI International, USADOI: doi.org/10.1182/bloodadvances.2020001701
read more
+myBinderRelated Content
-
Opioid Abuse Backlash Could Hurt Sickle Cell Patients’ Medication Needs, Some FearWith drug overdoses now the leading caus...
-
Sending a Child With Sickle Cell Disease off to CollegeSickle cell disease afflicts about 100,0...
-
The Unveiling of Sickle Cell Anemia – A Life’s StoryThe doctors and nurses that I trusted so...
-
Individuals with Disabilities Education Act (IDEA)The U.S. Department of Education’s Ind...
-
Impact of Spiritual Counseling for African American Young Adults with Sickle Cell DiseaseThis spiritual intervention addresses th...
-
Accommodation and Compliance: Sickle Cell AnemiaSickle cell anemia, or sickle cell disea...
-
Boston public schools agree to recognize sickle cell disease as disabilityThe Boston school system has agreed to r...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.